American Thoracic Society news tips for November (first issue)

November 05, 2002

Anti-inflammatory agents work best in sepsis patients at greatest risk of death

The efficacy of treatment with anti-inflammatory agents for sepsis depends on the severity of the underlying disease as manifested by risk of death, according to National Institutes of Health investigators publishing in the American Thoracic Society's peer-reviewed journal. (Sepsis is a disease involving excess bacteria in the bloodstream that, if not treated early, can lead to other severe infections at various sites throughout the body.) The biomedical scientists performed a retrospective analysis of 22 published clinical studies and 38 pre-clinical animal trials, along with a prospective large confirmatory animal investigation. The researchers were testing their hypothesis that anti-inflammatory agents were more efficacious in sepsis patients who had a higher risk of death and harmful in those with low risk. They believe that the consistency among the trials strongly supported their hypothesis that risk of death alters the effects of anti-inflammatory agents during sepsis. After looking at the published human clinical trials and pre-clinical animal data, they tested their ideas on 1,296 rats at varying doses of infectious agents. They found that regardless of the type of anti-inflammatory agents used, the drugs were more effective at a severity associated with higher death rates. The research appears in the first issue for November 2002 of the American Journal of Respiratory and Critical Care Medicine.

Lung cancer--where are we today?

Spiral computed tomography (CT) of the chest performed in middle-aged smokers can help identify two to four times more lung cancers than chest x-ray, with more than 70 percent of the tumors still in Stage 1, according to a "State of the Art" article on lung cancer in the first issue for November of the American Thoracic Society's peer-reviewed journal. The authors note that since spiral CT detects a high percentage of benign nodules, positron emission tomography scanning is used to confirm the disease stage since the latter procedure is more sensitive, specific, and accurate. The article states that, worldwide, lung cancer is the commonest cancer in men and women. It has a greater total incidence than that of colorectal, cervical, and breast cancer combined. In 2001, lung cancer caused more than 1 million deaths worldwide. In the United States, the disease accounts for 28 percent of all cancer deaths each year. The authors point out that by year 2000 the disease had become one of the leading causes of preventable death, since smoking has been known as its major cause for over 40 years. Because surgical resection or radical radiotherapy can cure only 10 percent of all patients with non-small cell lung cancer (NSCLC), 90 percent will either be first diagnosed with or develop advanced disease from which they will ultimately die. Virtually no evidence exists that chemotherapy can cure NSCLC. Small cell lung cancer (SCLC) comprises about 20 percent of the disease. Since it is sensitive to several chemotherapeutic agents, it will elicit a 50 percent or more reduction in tumor size in greater than 30 percent of previously untreated patients. Limited disease SCLC is treated by both chemotherapy and chest irradiation. The three-year survival rates from this process have climbed to between 20 and 30 percent. The authors stress that communities and countries that institute a smoking ban probably would achieve far more in the long-term than physicians can currently with all available treatments for the disease. The study appears in the first issue for November of the American Journal of Respiratory and Critical Care Medicine.
For the complete text of these articles, please see the American Thoracic Society Online Web Site at For contact information or to request a complimentary journalist subscription to ATS journals online, or if you would like to add your name to the Society's twice monthly journal news mailing list (please select either postal or electronic delivery), contact Cathy Carlomagno at (212) 315-6442, or by e-mail at

American Thoracic Society

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to